$TRAW
Traws Pharma, Inc. Stock $traw

$traw Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000110465913068496 Filed on September 06, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$1.116M	$591.0K	$220.0K
YoY Change	-97.39%	168.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.930M	$3.120M	$1.630M
YoY Change	-33.52%	91.41%
% of Gross Profit
Research & Development	$15.29M	$10.05M	$6.776M
YoY Change	-43.28%	48.27%
% of Gross Profit
Depreciation & Amortization	$120.0K	$110.0K	$80.00K
YoY Change	71.43%	37.5%
% of Gross Profit
Operating Expenses	$21.22M	$13.16M	$8.403M
YoY Change	-40.87%	56.66%
Operating Profit	-$20.10M	-$12.57M	-$8.183M
YoY Change	-390.56%	53.65%
Interest Expense	$1.000K	$2.000K	$230.0K
YoY Change	-99.99%	-99.13%
% of Operating Profit
Other Income/Expense, Net	$47.00K	$13.00K	-$2.000K
YoY Change	67.86%	-750.0%
Pretax Income	-$20.09M	-$12.56M	-$7.416M
YoY Change	1299.93%	69.39%
Income Tax	$432.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.52M	-$12.56M	-$7.416M
YoY Change	1330.03%	69.39%
Net Earnings / Revenue	-1838.8%	-2125.55%	-3370.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.052B	-$11.72B	-$8.636B
COMMON SHARES
Basic Shares Outstanding	21.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$116.6M	$51.20M
YoY Change
Cash & Equivalents	$76.61M	$51.18M	$2.522M
Short-Term Investments	$40.00M
Other Short-Term Assets	$395.0K	$1.183M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$121.9M	$57.05M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$652.0K	$729.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.00K	$12.00K
YoY Change
Total Long-Term Assets	$789.0K	$866.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$121.9M	$57.05M
Total Long-Term Assets	$789.0K	$866.0K
Total Assets	$122.7M	$57.91M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.405M	$4.410M
YoY Change
Accrued Expenses	$7.400M	$5.300M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.83M	$13.31M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$30.00K	$47.00K
YoY Change
Total Long-Term Liabilities	$30.00K	$47.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.83M	$13.31M
Total Long-Term Liabilities	$30.00K	$47.00K
Total Liabilities	$28.89M	$27.49M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$216.3M	-$195.8M
YoY Change
Common Stock	$310.1M	$22.81M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$93.83M	-$172.9M	-$158.7M
YoY Change
Total Liabilities & Shareholders Equity	$122.7M	$57.91M
YoY Change

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$20.52M	-$12.56M	-$7.416M
YoY Change	1330.03%	69.39%
Depreciation, Depletion And Amortization	$120.0K	$110.0K	$80.00K
YoY Change	71.43%	37.5%
Cash From Operating Activities	-$14.37M	-$15.93M	-$6.160M
YoY Change	-134.54%	158.6%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	-$190.0K	-$10.00K
YoY Change	-58.33%	1800.0%
Acquisitions
YoY Change
Other Investing Activities	-$39.99M
YoY Change
Cash From Investing Activities	-$40.04M	-$190.0K	-$10.00K
YoY Change	33266.67%	1800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	79.85M	0.000	8.420M
YoY Change	24.47%	-100.0%
NET CHANGE
Cash From Operating Activities	-14.37M	-15.93M	-6.160M
Cash From Investing Activities	-40.04M	-190.0K	-10.00K
Cash From Financing Activities	79.85M	0.000	8.420M
Net Change In Cash	25.44M	-16.12M	2.250M
YoY Change	-75.92%	-816.44%
FREE CASH FLOW
Cash From Operating Activities	-$14.37M	-$15.93M	-$6.160M
Capital Expenditures	-$50.00K	-$190.0K	-$10.00K
Free Cash Flow	-$14.32M	-$15.74M	-$6.150M
YoY Change	-134.32%	155.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Revenues Revenues	1707000	USD
	dei	Entity Registrant Name EntityRegistrantName	Onconova Therapeutics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001130598
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21403655	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81527000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2522000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1725000	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5867000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	83252000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	57048000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	463000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	729000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	125000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	125000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195760000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-158306000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-172942000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83852000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57914000	USD
CY2012Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	18548253	shares
CY2013Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	18548253	shares
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16912199	shares
CY2012Q4	us-gaap	Assets Assets	83852000	USD
CY2013Q2	us-gaap	Assets Assets	57914000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5517000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4410000	USD
CY2012Q4	ontx	Accrued Expenses And Other Current Liabilities Current AccruedExpensesAndOtherCurrentLiabilitiesCurrent	3925000	USD
CY2013Q2	ontx	Accrued Expenses And Other Current Liabilities Current AccruedExpensesAndOtherCurrentLiabilitiesCurrent	5338000	USD
CY2012Q4	ontx	Warrant Liability Current WarrantLiabilityCurrent	62000	USD
CY2013Q2	ontx	Warrant Liability Current WarrantLiabilityCurrent	50000	USD
CY2012Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	11967000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3907000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3509000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25378000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13307000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15421000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14136000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	40843000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	27490000	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	201315000	USD
CY2013Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	203366000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10021000	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	22787000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168353000	USD
CY2013Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16912199	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16912199	shares
CY2013Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16912199	shares
CY2013Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	205760000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30145155	shares
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30145155	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2606484	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2606484	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2609484	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2609484	shares
CY2012Q2	us-gaap	Revenues Revenues	220000	USD
CY2013Q2	us-gaap	Revenues Revenues	591000	USD
	us-gaap	Revenues Revenues	418000	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1627000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3117000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4087000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6463000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6776000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10047000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15224000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22803000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	8403000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	13164000	USD
	us-gaap	Operating Expenses OperatingExpenses	19311000	USD
	us-gaap	Operating Expenses OperatingExpenses	29266000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8183000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12573000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27559000	USD
CY2012Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-999000	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-390000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	230000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	251000	USD
	us-gaap	Interest Expense InterestExpense	2000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	539000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7416000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12562000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18215000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-27407000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-12562000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18215000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27407000	USD
CY2012Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	927000	USD
CY2013Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1032000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2158000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2051000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8343000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13594000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20373000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29458000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.84
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-11.29
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2173549	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2609495	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2173549	shares
CY2013Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-2000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	5000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7416000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12564000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18215000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27402000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-138419000	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-158749000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	USD
	ontx	Adjustments To Additional Paid In Capital Share Based Compensation Settlement Of Option Liability AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSettlementOfOptionLiability	34000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-2158000	USD
	ontx	Adjustments To Additional Paid In Capital Share Based Modification Of Stock Option Awards AdjustmentsToAdditionalPaidInCapitalShareBasedModificationOfStockOptionAwards	14482000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	44000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	291000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-2051000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	207000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2540000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2844000	USD
	ontx	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	-19000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-177000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4142000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2532000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1107000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2644000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1413000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-20000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3373000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1683000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12247000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-29884000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	473000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-473000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2167000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	400000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9486000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12062000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	5000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-191000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-30346000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2713000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51181000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3081644	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2285803	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3081644	shares
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2284000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1555000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1811000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1348000	USD
CY2013Q2	ontx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3972000	USD
CY2013Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	818000	USD
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	548000	USD
CY2012Q4	ontx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	3521000	USD
CY2012Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	247000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	157000	USD
	ontx	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Increase In Number Of Shares Reserved For Issuance Equal To Fully Diluted Shares Calculated Annually ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfIncreaseInNumberOfSharesReservedForIssuanceEqualToFullyDilutedSharesCalculatedAnnually	0.17	pure
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2285803	shares
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	379000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2540000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2843000	USD
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2351000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y29D
CY2013Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2796519	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y3M7D
CY2013Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1790647	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2013Q2	ontx	Number Of Clinical Stage Product Candidates NumberOfClinicalStageProductCandidates	3	item
CY2013Q2	ontx	Number Of Preclinical Programs NumberOfPreclinicalPrograms	6	item
CY2013Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2285000	USD
	ontx	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1	item
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10857939	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15639243	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1. Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">The Company</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 25pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Onconova Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company’s headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using its proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The Company believes that the drug candidates in its pipeline have the potential to be efficacious in a wide variety of cancers without causing harm to normal cells. The Company has three clinical-stage product candidates and six preclinical programs. To accelerate and broaden the development of rigosertib, the Company’s most advanced product candidate, the Company entered into a collaboration and license agreement with Baxter Healthcare SA (“Baxter”), a subsidiary of Baxter International Inc., in 2012 to commercialize rigosertib in Europe. In 2011, the Company entered into a collaboration and license agreement with SymBio Pharmaceuticals Limited (“SymBio”) to commercialize rigosertib in Japan and Korea. The Company has retained development and commercialization rights to rigosertib in the rest of the world, including the United States. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Liquidity</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has incurred recurring operating losses since inception. For the six months ended June 30, 2013, the Company incurred a net loss of $27,407,000 and as of June 30, 2013, the Company had generated an accumulated deficit of $195,760,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its product candidates and its preclinical programs, strategic alliances and the development of its administrative organization.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 22pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has raised significant capital through the issuance of its redeemable convertible preferred stock, par value $0.01 per share, in ten series denominated as Series A through Series J (“Series A Preferred Stock” through “Series J Preferred Stock,” respectively, and collectively the “Preferred Stock”). See Note 6.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 24pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On July 30, 2013, the Company completed its initial public offering (the “IPO”) of 5,941,667 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price of $15.00 per share, including 775,000 shares of Common Stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the same price to cover over-allotments. The Company received net proceeds of $79,600,000 from the sale, net of underwriting discounts and commissions and other estimated offering expenses. I</font><font style="FONT-SIZE: 10pt;" size="2">mmediately prior to the consummation of the IPO, all outstanding shares of Preferred Stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect.  As a result of the conversion, as of July 30, 2013, the Company had no shares of Preferred Stock outstanding.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 26pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development and commercial programs and meet its obligations. Management intends to fund future operations through additional equity offerings, licensing revenue, grants, government contracts and, if any of the Company’s product candidates receive marketing approval, future sales of its products. There can be no assurance, however, that the Company will be successful in obtaining financing at the level needed to sustain operations or on terms acceptable to the Company, or that the Company will obtain approvals necessary to market its products or achieve profitability or sustainable, positive cash flow.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 25.9pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company faces many risks associated with companies in the early stages. It also faces risks inherent in its business and its industry generally. These risks include, among others, the following:</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company’s success is primarily dependent on the regulatory approval and commercialization of rigosertib;</font></p> <p style="MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company is subject to regulatory approval processes that are lengthy, time consuming, expensive and unpredictable. The Company may not obtain approval on a timely basis or at all for any of its product candidates from the U.S. Food and Drug Administration or foreign regulatory authorities;</font></p> <p style="MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company has no significant source of product revenue, may never become profitable and may incur substantial and increasing net losses for the foreseeable future as it continues to develop and seek regulatory approvals for, and potentially begins to commercialize, its product candidates;</font></p> <p style="MARGIN: 0in 0in 0pt 0.25in;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company may need to obtain additional funding to continue operations;</font></p> <p style="TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">it is difficult and costly to protect the Company’s intellectual property rights;</font></p> <p style="TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company may be unable to recruit or retain key employees, including its senior management team; and</font></p> <p style="TEXT-INDENT: 0.25in; MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt 25.9pt;"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt;" size="2">·</font> <font style="FONT-SIZE: 10pt;" size="2">the Company depends on the performance of third parties, including contract research organizations and third-party manufacturers.</font></p> </div>
CY2012Q4	ontx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	1429000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	296000	USD
CY2013Q2	ontx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	2399000	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1183000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2012	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2012Q4	ontx	Number Of New Programs To Be Collaborated And Developed By Joint Venture NumberOfNewProgramsToBeCollaboratedAndDevelopedByJointVenture	2	item
CY2013Q2	ontx	Number Of Group Companies Of Which Average Historical Share Price Trading Data Used For Estimation Of Volatility NumberOfGroupCompaniesOfWhichAverageHistoricalSharePriceTradingDataUsedForEstimationOfVolatility	11	item
	ontx	Number Of Series Denominations Of Preferred Stock NumberOfSeriesDenominationsOfPreferredStock	10	item

Files In Submission

Name	View Source	Status
0001104659-13-068496-index-headers.html	Edgar Link	pending
0001104659-13-068496-index.html	Edgar Link	pending
0001104659-13-068496.txt	Edgar Link	pending
0001104659-13-068496-xbrl.zip	Edgar Link	pending
a13-19124_110q.htm	Edgar Link	pending
a13-19124_1ex31d1.htm	Edgar Link	pending
a13-19124_1ex31d2.htm	Edgar Link	pending
a13-19124_1ex32d1.htm	Edgar Link	pending
a13-19124_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ontx-20130630.xml	Edgar Link	completed
ontx-20130630.xsd	Edgar Link	pending
ontx-20130630_cal.xml	Edgar Link	unprocessable
ontx-20130630_def.xml	Edgar Link	unprocessable
ontx-20130630_lab.xml	Edgar Link	unprocessable
ontx-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TRAW
Traws Pharma, Inc. Stock $traw

2013 Q3 Form 10-Q Financial Statement

#000110465913068496 Filed on September 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRAW Traws Pharma, Inc. Stock $traw

2013 Q3 Form 10-Q Financial Statement

#000110465913068496 Filed on September 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TRAW
Traws Pharma, Inc. Stock $traw